Search
Iovance Biotherapeutics Inc
IOVAAdd to Watchlist
4.070USD
-0.620-13.22%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.82BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Iovance Biotherapeutics Inc is 7.64, ranking 280 out of 385 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 17.00 and a low of 1.50.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
8.800
Target Price
+116.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Iovance Biotherapeutics Inc
IOVA
10
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Iovance Biotherapeutics Inc's expected revenue for the next quarter?
Iovance Biotherapeutics Inc's expected revenue is 87.67M.
What is Iovance Biotherapeutics Inc's price target?
Analysts forecast that Iovance Biotherapeutics Inc's price target is USD 9.00, with the highest forecast at USD 17.00 and the lowest forecast at USD 1.50.
How have Iovance Biotherapeutics IncIOVA's recent earnings per share performed?
The market expectation was USD -0.19, while Iovance Biotherapeutics IncIOVA's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for Iovance Biotherapeutics Inc?
Based on the ratings of Iovance Biotherapeutics Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.